GRANT OF RIGHTS AGREEMENTGrant of Rights Agreement • July 7th, 2023
The undersigned, acting on his/her own behalf as holder of the copyright to the above-mentioned paper (the “Paper”), or as the authorised representative of the person or entity holding the copyright, grants the OECD/NEA the publication rights to the Paper, royalty-free, for the full period of copyright. This assignment includes the right to publish, distribute and sell (or license others to publish, distribute and sell), selections, abridgments, re-editions, reprints, translations or adaptations of the Paper in either print or electronic form, or any other medium of publication or presentation, throughout the world without exception.
Ich habe einen Traum – I Have a DreamGrant of Rights Agreement • June 5th, 2020
We are so pleased that you are participating in the German Federal Foreign Office’s ebook entitled ‘Ich habe einen Traum – I have a Dream’!
TERMS AND CONDITIONSGrant of Rights Agreement • June 1st, 2015
DATE: 15th May, 2017Grant of Rights Agreement • May 15th, 2017
GRANT OF RIGHTS AGREEMENTGrant of Rights Agreement • January 7th, 2021
The undersigned, acting on his/her own behalf as holder of the copyright to the above-mentioned paper (the “Paper”), or as the authorised representative of the person or entity holding the copyright, grants the OECD/NEA the publication rights to the Paper, royalty-free, for the full period of copyright. This assignment includes the right to publish, distribute and sell (or license others to publish, distribute and sell), selections, abridgments, re-editions, reprints, translations or adaptations of the Paper in either print or electronic form, or any other medium of publication or presentation, throughout the world without exception.
GRANT OF RIGHTS, REPRESENTATIONS AND WARRANTIESGrant of Rights Agreement • April 19th, 2016
Vifor (International) Ltd. Rechenstrasse 37 CH-9014 St. Gallen SwitzerlandGrant of Rights Agreement • August 9th, 2018 • ChemoCentryx, Inc. • Pharmaceutical preparations
As you know, Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and ChemoCentryx, Inc. (“ChemoCentryx”) are parties to that certain Collaboration and License Agreement, dated December 22, 2016 (the “VFMCRP Agreement”), pursuant to which ChemoCentryx granted VFMCRP an exclusive license to commercialize ChemoCentryx’s proprietary C5aR inhibitor known as CCX140 in certain countries. Capitalized terms used but not otherwise defined in this letter agreement (this “Letter”) will have the meanings provided in the VFMCRP Agreement. The VFMCRP Agreement was originally entered into between Vifor (International) Ltd. (“Vifor”) and ChemoCentryx and was subsequently assigned by Vifor to VFMCRP, so that references in the VFMCRP Agreement to VIT now refer to VFMCRP.
AGREEMENT made and entered into as of (Date) by and betweenGrant of Rights Agreement • October 13th, 2020 • California
(the "Director"), the American Film Institute ("AFI”) and (the "Grantor") relating to the motion picture with the Production Number # currently titled
